In vitro and in vivo activities of DS-2969b, a novel GyrB inhibitor, against Clostridium difficile.
about
A Phase 1 Study in Healthy Subjects to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Oral Doses of DS-2969b, a Novel GyrB Inhibitor.In vitro and in vivo activities of DS-2969b, a novel GyrB inhibitor, and its water-soluble prodrug, DS11960558, against methicillin-resistant Staphylococcus aureus.
P2860
In vitro and in vivo activities of DS-2969b, a novel GyrB inhibitor, against Clostridium difficile.
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh-hant
name
In vitro and in vivo activitie ...... against Clostridium difficile.
@en
In vitro and in vivo activitie ...... against Clostridium difficile.
@nl
type
label
In vitro and in vivo activitie ...... against Clostridium difficile.
@en
In vitro and in vivo activitie ...... against Clostridium difficile.
@nl
prefLabel
In vitro and in vivo activitie ...... against Clostridium difficile.
@en
In vitro and in vivo activitie ...... against Clostridium difficile.
@nl
P2093
P2860
P356
P1476
In vitro and in vivo activitie ...... against Clostridium difficile.
@en
P2093
Diksha Singh
Dilip Jatashankar Upadhyay
Makiko Yamada
Manoj Kumar Khera
Manoj Kumar
Nobuhisa Masuda
Shin-Ichi Inoue
Tarani Kanta Barman
Tarun Mathur
P2860
P356
10.1128/AAC.02157-17
P407
P577
2018-02-12T00:00:00Z